| Popis: |
Lisa Dwyer Orr,1 Dee Lin,1 Bingcao Wu,1 Thomas W LeBlanc,2 Beth Faiman,3 Jenny Ahlstrom,4 Margaret Yung,5 Kathleen L Deering,5 Victoria Kulbokas,5 Joshua L Feldman,6 Erika Kline,6 Noa Biran7 1Janssen Scientific Affairs LLC, Titusville, NJ, USA; 2Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA; 3Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA; 4HealthTree Foundation, Draper, UT, USA; 5EPI-Q Inc, Chicago, IL, USA; 6Inspire Insights, Arlington, VA, USA; 7Hackensack Meridian Health, John Theurer Cancer Center, Hackensack, NJ, USACorrespondence: Lisa Dwyer Orr, Janssen Scientific Affairs LLC, Titusville, NJ, USA, Tel +1 561 290-9901, Email LDwyer2@ITS.JNJ.comIntroduction: Treatment decision-making for multiple myeloma (MM) is complex. Individuals involved in decision-making may value treatment attributes differently based on their role as a patient, care partner, or physician. This study describes those attributes, and what is most important by role.Methods: We conducted a cross-sectional online survey with consenting adult patients with MM, MM care partners, and physicians treating MM. Respondents were recruited from US panels (Inspire and M3 Global Research) between September and December 2022. Survey items were informed by a targeted literature review, qualitative interviews, and a steering committee comprising clinical experts, a patient advocate, patient, and care partner. Descriptive statistics were generated and reported in aggregate.Results: Email invitations were sent to 8071 Inspire members interested in or posting about MM. Of these, 4427 viewed the invitation, 941 responded, and 156 patients and care partners completed the survey (17% of respondents). For physicians, 5588 were invited via Email by M3 Global Research, with 761 viewing the invitation, 214 accessing the survey link, and 137 completing the survey (64% of respondents). Duration of response, side effects, and patients’ quality-of-life (QoL) were the top three treatment attributes selected across the three cohorts; alignment of these attributes was consistent among patients regardless of disease severity. Separately, patients rated QoL and the amount of caregiving needed during/after treatment as the most important factors for future treatment decisions. If more effective MM treatments were offered, care partners were more willing to assume greater family burden (77%) compared to patients (49%), and patients were more accepting of potential serious side effects (50%) than were care partners (34%).Conclusion: Patients with MM, care partners, and physicians consider and value various treatment decision-making factors. Recognizing and addressing these differences is critical to meeting patients’ preferences, needs, and optimizing patient outcomes.Keywords: Decision-making, treatment choice, cross-sectional survey, multiple myeloma |
